Vertex Pharma leads biotech this week, shares hover near record highs

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 09:38.

Vertex Pharma (US92532F1003) sits among the leading biotech names on the NASDAQ this week. The shares are part of the S&P 500 health-care sector and have posted a marked year-to-date gain compared with several large-cap peers.

How Vertex compares to peers

Vertex Pharma shares trade on NASDAQ under the ticker VRTX, alongside major biotech names such as Amgen and Gilead Sciences in the S&P 500 health-care cohort. MarketBeat overview on Vertex Pharmaceuticals The stock closed at 480.18 US dollars on 2026-06-25, up 1.05 percent for the day, which keeps it close to its 12-month highs.

Compared with the broader biotech group, Vertex Pharma shows a robust multi-year performance supported by recurring profitability, whereas many pipeline-focused peers still rely on single assets or yet-unapproved candidates. Vertex-related sector news on MarketBeat For retail investors watching the US biotech space, the stock offers a contrast between established cash generation and the volatility typical of earlier-stage companies.

What the numbers show for 2026

For the first quarter of 2026, Vertex Pharma reported earnings per share of 4.47 US dollars, beating the consensus estimate of 4.24 US dollars by 0.23 US dollars according to MarketBeat. Vertex Pharmaceuticals earnings summary Q1 2026 This beat underlines a continued pattern of solid execution, with profitability supporting the current valuation levels.

The 480.18 US dollar closing price on 2026-06-25 reflects a gain of 4.98 US dollars, or 1.05 percent, compared with the previous trading day. StockScan price snapshot for VRTX In after-hours trading, the shares were quoted slightly higher, signalling ongoing investor interest going into the next US trading session.

The business behind the stock

Vertex Pharma generates most of its revenue from therapies for cystic fibrosis, led by its flagship combination medicine Trikafta in the United States and other key markets. Vertex overview of approved medicines These treatments target the underlying cause of the disease in patients with specific CFTR gene mutations.

Beyond cystic fibrosis, the company invests heavily in a pipeline focused on genetic and serious diseases, including programs in sickle cell disease and type 1 diabetes, with multiple clinical-stage candidates. Vertex investor materials on pipeline strategy This combination of established products and late-stage pipeline projects shapes how investors assess the long-term earnings power of the stock.

Where the shares trade today

The Vertex Pharma shares (US92532F1003) trade on 2026-06-25 on NASDAQ at 480.18 US dollars as of 16:00 Eastern time, with an after-hours indication modestly above that level in US trading.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or a solicitation of any kind. Historical performance is not a reliable indicator of future results.